Clearmind Medicine Inc. Common Shares (CMND) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.82 (-4.46%), Market cap $0.00B, 52-week low–high $0.07 ~ $2.80.
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a collaboration with Sci
Financial statements, price targets, institutional (13F) holdings and related news for Clearmind Medicine Inc. Common Shares are updated in real time on BlackAll Trade.
Clearmind Medicine Inc. Common Shares trades at $0.82 (-4.46%). Real-time quotes and charts are available on BlackAll Trade.
Clearmind Medicine Inc. Common Shares has a market cap of about $0.00B.
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders,